RCM
LAB icon

RA Capital Management’s Standard BioTools LAB Stock Holding History

RA Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,987,589
Closed -$3.18M – 89
2022
Q2 		$3.18M Buy
+1,987,589
New +$4.92M 0.08% 74

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JCP
Jennifer C. Price $75.5M AUM 6.25% 1-Year Est. Return

RA Capital Management's LAB Position: Q3 2022 in Review

RA Capital Management sold out of Standard BioTools (LAB) in Q3 2022, closing a stake of 1,987,589 shares — an estimated $3.18M sold.

RA Capital Management first reported a position in LAB in Q2 2022 and held it in 1 quarter. The position peaked at $3.18M in Q2 2022. 65 funds tracked by Wall St. Rank hold LAB as of Q3 2022.

  • RA Capital Management reported no remaining Standard BioTools position as of Q3 2022 after selling out during the quarter.
  • RA Capital Management sold 1,987,589 Standard BioTools shares in Q3 2022, an estimated $3.18M.
  • RA Capital Management first reported a position in Standard BioTools in Q2 2022 and held it in 1 quarter.
  • RA Capital Management's Standard BioTools position peaked at $3.18M in Q2 2022.
  • 65 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2022.

Based on RA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.